The optic nerve of the eye is a second cranial nerve which transports electrical impulses from photoreceptor cells in the retina of the eye to the visual cortex in the brain. The steroid-based medications such as methylprednisolone, a synthetic corticosteroid administered intravenously as an anti-inflammatory and immunosuppressive treatment.
Increasing geriatric population suffering from eye diseases, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support
Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to The evolving healthcare regulatory landscape and the government's emphasis on enhancing R&D capabilities for innovative product development.
Top companies such as AbbVie Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG and Pfizer, Inc. held a high market position in 2021.
Immunomodulators segment is the most influencing segment owing to increase in research and development activities for the manufacturing of immunomodulators for optic nerve disorder treatments along with increase in number of key players has resulted surge in the launch of novel drugs which further boost the market growth.
The forcast period for healthcare assistive robot is 2022 to 2031
The base year is 2021 in optic nerve disorder treatment market
The market value of optic nerve disorder treatment market in 2031 is $5,247.82 million.
The total market value of optic nerve disorder treatment marketis $3,372.46 million in 2021.
Loading Table Of Content...
Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?